Cargando…

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

INTRODUCTION: Multilineage myelosuppression is an acute toxicity of cytotoxic chemotherapy, resulting in serious complications and dose modifications. Current therapies are lineage specific and administered after chemotherapy damage has occurred. Trilaciclib is a cyclin-dependent kinase 4/6 inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hart, Lowell L., Ferrarotto, Renata, Andric, Zoran G., Beck, J. Thaddeus, Subramanian, Janakiraman, Radosavljevic, Davorin Z., Zaric, Bojan, Hanna, Wahid T., Aljumaily, Raid, Owonikoko, Taofeek K., Verhoeven, Didier, Xiao, Jie, Morris, Shannon R., Antal, Joyce M., Hussein, Maen A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854399/ https://www.ncbi.nlm.nih.gov/pubmed/33123968 http://dx.doi.org/10.1007/s12325-020-01538-0

Ejemplares similares

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
por: Weiss, J M, et al.
Publicado: (2019)

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
por: Li, Chao, et al.
Publicado: (2021)

Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer
por: Dómine Gómez, Manuel, et al.
Publicado: (2021)

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
por: Hussein, Maen, et al.
Publicado: (2021)

Pharmacokinetic Drug–Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer
por: Li, Chao, et al.
Publicado: (2022)

Low-Cost Genetic and Clinical Predictors of Response and Toxicity of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer
por: Spasic, Jelena, et al.
Publicado: (2022)

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
por: Johnson, Melissa L, et al.
Publicado: (2023)

Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy
por: Goldschmidt, Jerome, et al.
Publicado: (2023)

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial
por: Daniel, Davey, et al.
Publicado: (2021)

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
por: Chiappori, Alberto A., et al.
Publicado: (2016)

Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer
por: Powell, Kerrington, et al.
Publicado: (2021)

Hyoid Bone and Thyroid Cartilage Metastases from Sigmoid Colon Adenocarcinoma: A Case Report
por: Bracanovic, Djurdja, et al.
Publicado: (2017)

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
por: Ferrarotto, Renata, et al.
Publicado: (2021)

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer
por: Tan, Antoinette R., et al.
Publicado: (2023)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials
por: Qiu, Jingyue, et al.
Publicado: (2023)

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

Periocular topotecan for vitreous seeds in retinoblastoma
por: Sthapit, Purnima R, et al.
Publicado: (2018)

Neoadjuvant chemotherapy in the setting of locally advanced olfactory neuroblastoma with intracranial extension
por: Aljumaily, Raid M., et al.
Publicado: (2011)

Evaluation of Clinical and Genetic Determinants of Treatment OutCome In EGFR Mutation Positive Advanced Lung Adenocarcinoma
por: Jokic, Vera, et al.
Publicado: (2022)

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
por: Nazha, Bassel, et al.
Publicado: (2020)

Clinicopathological features and relation between anaplastic lymphoma kinase (ALK) mutation and histological subtype of lung adenocarcinoma in Eastern European Caucasian population
por: Zaric, Bojan, et al.
Publicado: (2016)

Optimization of liposomal topotecan for use in treating neuroblastoma
por: Chernov, Lina, et al.
Publicado: (2017)

Development and Validation of an HPLC Method for Analysis of Topotecan in Human Cerebrospinal Fluid and Its Application in Elimination Evaluation of Topotecan after Intraventricular Injection
por: Yoshikawa, Naoki, et al.
Publicado: (2021)

The Lipophilic Purine Nucleoside—Tdp1 Inhibitor—Enhances DNA Damage Induced by Topotecan In Vitro and Potentiates the Antitumor Effect of Topotecan In Vivo
por: Chernyshova, Irina A., et al.
Publicado: (2022)

Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999)

A phase I and pharmacokinetic study of intraperitoneal topotecan
por: Hofstra, L S, et al.
Publicado: (2001)

Topotecan in the treatment of relapsed small cell lung cancer
por: Quoix, Elisabeth
Publicado: (2008)

Carboplatin +/− Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma
por: Francis, Jasmine H., et al.
Publicado: (2013)

Adverse drug reaction after intravitreal injection of topotecan
por: Narang, Subina, et al.
Publicado: (2020)

Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
por: Tan, Antoinette R., et al.
Publicado: (2022)

Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion
por: Das, Millie, et al.
Publicado: (2021)

Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
por: Nazha, Bassel, et al.
Publicado: (2022)

A review of topotecan in combination chemotherapy for advanced cervical cancer
por: Robati, Minoo, et al.
Publicado: (2008)

Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.
por: Vukovic, V., et al.
Publicado: (1997)

Assessment of Anti-Cytogenotoxic Effects of Quercetin in Animals Treated with Topotecan
por: Bakheet, Saleh A.
Publicado: (2011)

Anticancer activities of genistein-topotecan combination in prostate cancer cells
por: Hörmann, Vanessa, et al.
Publicado: (2012)

Intraventricular Topotecan for the Treatment of Neoplastic Meningitis: Five Case Studies
por: Walker, Julie, et al.
Publicado: (2012)

Phase II Study to Topotecan and Cisplatin in Advanced Hepatocellular Carcinoma
por: Lee, Ga Young, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_jc2mran999mubnne72a5iu77oo